Harrow has announced an initiative to expand access and affordability for its ophthalmic pharmaceutical products. This includes a program of targeted price reductions for several Harrow products and a ...
The new PDUFA goal date for NT-501 as treatment for macular telangiectasia type 2 (MacTel) is March 18, 2025. The US Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act ...
A press release from the NIH announced that its scientific team has defined elements of brain-based visual impairment in children. Cerebral or cortical visual impairment (CVI) “has emerged as a ...
LUNA is an ongoing double-masked, randomized Phase 2 trial. OPTIC is an ongoing, open-label, dose-ranging first-in-human ...
ARVN001 is indicated for the treatment of uveitic macular edema (UME) and certain other ophthalmic indications under development. Arctic Vision has signed a new commercial collaboration agreement with ...
Gregg T. Kokame, MD, MMM, FASRS, is set to share data from a predefined subgroup of the sozinibercept Phase 2b wet AMD trial related to patients with polypoidal choroidal vasculopathy (PCV), measured ...
This year’s Barcelona meeting brought together award-winning research findings and leaders in the retina field. The European Society of Retina Specialists (Euretina) held its 24th annual congress in ...
Ocugen announces positive preliminary data from OCU410 Phase 1 clinical trial for geographic atrophy
Key findings include reduced lesion growth, retinal tissue preservation, and improved visual function, demonstrating significant potential for the treatment option. Ocugen Inc. announced positive ...
The FDA comments in the CRL relate to proposed labelling language, not safety, Astellas said in a press release.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback